INTRODUCTION

Suprachoroidal hemorrhage (SCH) is a rare complication of intraocular surgery that could be devastating and associated with permanent visual loss in some cases.\(^1\) The reported incidence of SCH during cataract surgery is 0.03–0.13%, usually occurring in patients with known systemic and ocular risk factors.\(^2\) Angiotensin-converting enzyme 2 is a receptor for SARS-CoV-2 and is highly expressed in ocular vascular endothelial cells. The choroid is the most densely vascularized tissue in the body.\(^3\)

Herein, we present two cases with a recent history of COVID-19 who developed SCH during uncomplicated phacoemulsification surgery.

CASE PRESENTATION

2.1 | Case 1

The first case was a 60-year-old man who underwent planned phacoemulsification cataract surgery in the left eye. His medical history was unremarkable. The patient had a documented positive polymerase-chain-reaction (PCR) test about 1 month before the surgery and the importance of postponing elective surgeries for several months after infection.

KEYWORDS

case report, cataract surgery, COVID-19, phacoemulsification, suprachoroidal hemorrhage
the iris prolapsed from the main incision. Intraoperative indirect ophthalmoscopy revealed temporal choroidal hemorrhage without the involvement of the posterior pole. The main corneal incision was sutured, and IOL insertion was postponed after the complete resorption of choroidal hemorrhage. The SCH was resolved within 4 weeks without any significant sequel (Figure 1). After the second surgery for IOL implantation, the final visual acuity returned to 20/20.

### 2.2 | Case 2

The second case was a 71-year-old woman (Table 1) who underwent planned phacoemulsification surgery in her right eye under general anesthesia. She did not have any history of systemic diseases except for controlled stage-1 hypertension. The patient had a history of COVID-19 infection confirmed by positive PCR 4 weeks before the operation.

This patient also developed limited SCH in the inferior retina during the irrigation and aspiration phase. However, we could insert the IOL in the same theater. SCH was almost resorbed in 3 weeks. The final BCVA was 20/25.

None of the cases had a history of COVID-19 vaccination, but their disease did not involve the lungs or required hospitalization, and they fully recovered within 2 weeks.
3 | DISCUSSION
COVID-19 exacerbation is partly attributed to a cytokine storm initiated by increasing levels of several pro-inflammatory cytokines. Meanwhile, significant endothelial cell injury increases vascular permeability and leakage. Although the lungs are the primary target for overwhelming inflammation and damage, several studies reported multiorgan failure due to systemic vascular involvement.

The choroid is the most densely vascularized tissue in the body. Angiotensin-converting enzyme 2 is a well-documented receptor for SARS-CoV-2 and is highly expressed in ocular vascular endothelial cells. So, in principle, choroidal and retinal vessels could be affected by COVID-19. In fact, recent studies reported microvascular and macrovascular retinal and choroidal changes in cases with COVID-19. Although such involvements for choroidal vessels are not clinically supported so far, subclinical injuries from cytokine storm to these vessels are quite possible and might be a risk factor for SCH in patients undergoing intraocular surgery during the recovery phase of COVID-19. This assumption is partly supported by the lack of known systemic or ocular risk factors of SCH in our patients and also their recent evident infection with COVID-19. In the same setting, we had a rate of approximately 0.03% for intraoperative SCH during phacoemulsification in the pre-COVID-19 era (all in patients with known risk factors, systemic risk factors include old age and arteriosclerosis, coagulation disorders, vascular hypertension, diabetes mellitus, intraoperative tachycardia, and ocular risk factors include high myopia, glaucoma, previous vitrectomy, pseudophakia, and aphakia), further increasing our suspicion of COVID-19 as a predisposing factor for SCH in patients mentioned above.

Recent COVID-19 infection might be a risk factor for SCH in patients undergoing cataract surgery. Although the two reported cases could not verify any cause-and-effect relationship, we should be vigilant about the possible association. Since COVID-19 has the potential to make many known and unknown changes to the human body, it is wise to postpone elective surgeries for several months after infection to let the body completely recovers itself.

CONFLICT OF INTEREST
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

DATA AVAILABILITY STATEMENT
It is on request from the authors. The data that support the findings of this study are available from the corresponding author upon reasonable request.

CONSENT
Written informed consent was obtained from the cases to publish this article and any accompanying image.

ORCID
Elham Sadeghi https://orcid.org/0000-0003-3802-3219

REFERENCES
1. Mo B, Li SF, Liu Y, Zhou J, Wang SL, Shi XY. Suprachoroidal hemorrhage associated with pars plana vitrectomy. BMC Ophthalmol. 2021;21(1):1-8.
2. Savastano A, Rizzo S, Savastano MC, et al. Choroidal effusion and suprachoroidal hemorrhage during phacoemulsification: intraoperative management to prevent expulsive hemorrhage. Eur J Ophthalmol. 2016;26(4):338-341.
3. Pereira LA, Soares LCM, Nascimento PA, et al. Retinal findings in hospitalized patients with severe COVID-19. Br J Ophthalmol. 2020;106:102-105.
4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
5. Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136(4):489-500.
6. Mondal R, Lahiri D, Deb S, et al. COVID-19: are we dealing with a multisystem vasculopathy in disguise of a viral infection? J Thromb Thrombolysis. 2020;50(3):567-579.
7. Landecho MF, Yuste JR, Gandara E, et al. COVID-19 retinal microangiopathy as an in vivo biomarker of systemic vascular disease? J Intern Med. 2020;289(1):116-120.
8. Zhang Y, Stewart JM. Retinal and choroidal manifestations of COVID-19. Curr Opin Ophthalmol. 2021;32(6):536-540.
9. Qureshi A, Jalil A, Sousa DC, et al. Outcomes of suprachoroidal haemorrhage drainage with and without vitrectomy: a 10-year study. Eye. 2021;35(7):1879-1885.

How to cite this article: Jamali A, Sadeghi E, Nowroozzadeh MH. Suprachoroidal hemorrhage during phacoemulsification surgery associated with recent COVID-19: A report of two cases. Clin Case Rep. 2022;10:e06204. doi: 10.1002/ccr3.6204